SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (521)5/20/2003 10:56:38 AM
From: Harold Engstrom  Respond to of 897
 
Tuck, Biogen and Elan to present at gastroenterology conference today: Crohn's treatment (Antegren.) If not today, then soon they will release PIII data. If approved for Crohn's then would expect off-label for MS right away. I am not really enthusiastic about Biogen, but think they are a bad short candidate.



To: tuck who wrote (521)5/20/2003 10:56:38 AM
From: Harold Engstrom  Respond to of 897
 
Tuck, Biogen and Elan to present at gastroenterology conference today: Crohn's treatment (Antegren.) If not today, then soon they will release PIII data. If approved for Crohn's then would expect off-label for MS right away. I am not really enthusiastic about Biogen, but think they are a bad short candidate.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News